The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6 year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD) A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C 11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid b (Ab) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C 11 Pittsburgh compound B PET, and CSF measurements of Ab and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.
Alzheimer's Dementia